Funding Opportunities

PDBP Funding opportunities (FOAs) support discovery projects designed to promote the identification of promising diagnostic and progression biomarkers for Parkinson's disease.

The NINDS Human Cell and Data Repository (U24 - Clinical Trial Not Allowed)

Annoucement Type:
Reissue of RFA-NS-15-009
Application Due Date:
Activity Code:
U24
Letter of Intent Due Date:
FOA Number:
RFA-NS-19-038
Contact:
Christine Swanson-Fischer, PhD

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications to support the National Institute of Neurological Disorders and Stroke (NINDS) Human Cell and Data Repository (NHCDR). The repository will maintain the current collection of fibroblast and induced pluripotent stem cell (iPSC) lines as well as develop, characterize, expand source cells and iPSCs, and where appropriate, genetically modify new high-quality iPSC lines in accordance with the NINDS mission. The NINDS Human Cell and Data Repository will distribute human cell resources broadly to qualified academic and industry researchers to advance basic and translational research in neurological disorders.

Peripheral Pathology in the Lewy Body Dementias (R01 Clinical Trial Not Allowed)

Annoucement Type:
New
Application Due Date:
Activity Code:
R01
FOA Number:
RFA-NS-20-014
Contact:
Debra Babcock, PhD, MD

Funding Opportunity Purpose

The purpose of this initiative is to identify potential diagnostic markers for the Lewy Body Dementias using non-blood or non-CSF peripheral specimens and tissues (e.g., skin, salivary gland, gastrointestinal tract, etc.). Blood and CSF have traditionally and extensively been examined for neurodegenerative disease biomarkers; however, research suggests that abnormal alpha-synuclein accumulation occurs in other peripheral tissues and specimens early in the disease course and may provide opportunities for early diagnosis and future treatment development.

Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33)

Annoucement Type:
New
Application Due Date:
Activity Code:
R61/R33
Letter of Intent Due Date:
FOA Number:
PAR-19-315
Contact:
Mary Ann Pelleymounter, PhD

Funding Opportunity Purpose

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological or neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary evaluation of the biomarker or biomarker signature in carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers and biomarker signatures that are ready for definitive analytical and clinical validation studies (see PAR-18-548PAR-18-549PAR-18-550 , PAR-19-220 and PAR-18-664).

Analytical Validation of a Candidate Biomarker for Neurological Disease (U01)

Annoucement Type:
New
Application Due Date:
Activity Code:
U01
Letter of Intent Due Date:
FOA Number:
PAR-18-550
Contact:
Mary Ann Pelleymounter, PhD; Julia Bachman, Ph.D.

Funding Opportunity Purpose

The overarching purpose of this Funding Opportunity Announcement (FOA) is to fill critical scientific gaps needed to advance strong candidate biomarkers of neurological disease from discovery to clinical use. Specifically, the focus of this FOA is on the validation of analytical methods for biomarker measurements, including evaluation of the assay, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines that are fit for the purpose of the assay.

Analytical Validation of a Candidate Biomarker for Neurological Disease (U44)

Annoucement Type:
New
Application Due Date:
Activity Code:
U44
Letter of Intent Due Date:
FOA Number:
PAR-18-549
Contact:
Mary Ann Pelleymounter, PhD; Christina Vert, MS; Stephanie Fertig, MBA

Funding Opportunity Purpose

The overarching purpose of this Funding Opportunity Announcement (FOA) is to fill critical scientific gaps needed to advance strong candidate biomarkers of neurological disease from discovery to clinical use. Specifically, the focus of this FOA is on the validation of analytical methods for biomarker measurements, including evaluation of the assay, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines that are fit for the purpose of the assay.

Clinical Validation of a Candidate Biomarker for Neurological Disease (U01)

Annoucement Type:
New
Application Due Date:
Activity Code:
U01
Letter of Intent Due Date:
FOA Number:
PAR-18-664
Contact:
Mary Ann Pelleymounter, PhD; Julia Bachman, Ph.D.

Funding Opportunity Purpose

The overarching purpose of this Funding Opportunity Announcement (FOA) is to fill critical scientific gaps needed to advance strong candidate biomarkers from discovery to clinical use. Specifically, the focus of this FOA is to support the clinical validation of candidate biomarkers of neurological disease using retrospective and/or prospective methods. Research supported by this FOA should demonstrate that biomarker change is reliably correlated with variables such as clinical outcome, disease progression, disease onset and severity, drug target engagement or response to a drug. In addition, biomarker response should be specific to the disease or therapeutic as demonstrated at multiple clinical sites.

Clinical Validation of a Candidate Biomarker for Neurological Disease (U44)

Annoucement Type:
New
Application Due Date:
Activity Code:
U44
Letter of Intent Due Date:
FOA Number:
PAR-18-548
Contact:
Mary Ann Pelleymounter, PhD; Julia Bachman, Ph.D.; Stephanie Fertig, MBA

Funding Opportunity Purpose

The overarching purpose of this Funding Opportunity Announcement (FOA) is to fill critical scientific gaps needed to advance strong candidate biomarkers from discovery to clinical use. Specifically, the focus of this FOA is to support the clinical validation of candidate biomarkers of neurological disease using retrospective and/or prospective methods. Research supported by this FOA should demonstrate that biomarker change is reliably correlated with variables such as clinical outcome, disease progression, disease onset and severity, drug target engagement or response to a drug. In addition, biomarker response should be specific to the disease or therapeutic as demonstrated at multiple clinical sites.

NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)

Annoucement Type:
Reissue of PAR-17-122
Application Due Date:
Activity Code:
U01
FOA Number:
PAR-18-420
Contact:
Peter Gilbert, ScM

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may include Phase 1 and 2 studies of drugs and biologics, feasibility studies of devices, and early studies of surgical, behavioral or rehabilitation therapies.  All exploratory trials must contribute to the justification for, and provide some of the data required to inform a future trial to establish efficacy (such as a Phase 3, Phase 4 or Pivotal trial).

NINDS Efficacy Clinical Trials (U01 Clinical Trial Required)

Annoucement Type:
Reissue of PAR-17-102
Application Due Date:
Activity Code:
U01
FOA Number:
PAR-18-422
Contact:
Peter Gilbert, ScM

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions.  These Phase 3, Phase 4 or Pivotal trials must address questions within the mission and research interests of the NINDS and may include studies of drugs, biologics, and devices, as well as surgical, behavioral or rehabilitation therapies.

Dissemination and Implementation Research in Health (R01, R21, R03)

Annoucement Type:
Reissue of PAR-18-007
Activity Code:
R01, R21, R03
FOA Number:
PAR-19-274
Contact:
Peter Gilbert, Sc.M.

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

Companion Funding Opportunity:

PAR-19-275, R21 Exploratory/Developmental Grant

PAR-19-276, R03 Small Grant Program  

Contact: Peter.Gilbert@nih.gov

Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01)

Annoucement Type:
Reissue of PAR-18-534
Application Due Date:
Activity Code:
U01
Letter of Intent Due Date:
FOA Number:
PAR-19-220
Contact:
Glen H. Nuckolls, Ph.D.

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.

Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3)

Annoucement Type:
New
Application Due Date:
Activity Code:
UG3/UH3
Letter of Intent Due Date:
FOA Number:
PAR-19-171
Contact:
Adam L. Hartman, MD

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered)). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.